Three private companies are merging to create a new entity in the psychedelics space.
Hollister Biosciences announces a private placement for CAD$1.5 million, expected to close by July 12, 2020.
Psychedelic drugs represent a potentially enormous step forward in treating an epidemic for which there are currently no good treatment options.
Eleusis Therapeutics is a private psychedelics company that is turning a lot of heads with its research on micro-doses of LSD as a treatment for Alzheimer's.
Mydecine's research agreement with the University of Alberta is a key stepping-stone in expediting its psilocybin-based drug development research.
New Wave Holdings Corp has added a recognized expert in psychedelic medicine to the company's Advisory Board.